Intuitive Surgical (NASDAQ:ISRG) Trading Down 0% - Time to Sell?

Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report)'s stock price fell 0% during mid-day trading on Wednesday . The stock traded as low as $596.47 and last traded at $600.85. 217,390 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 1,703,730 shares. The stock had previously closed at $600.89.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ISRG. JPMorgan Chase & Co. increased their price objective on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. UBS Group increased their price objective on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Evercore ISI increased their price objective on shares of Intuitive Surgical from $490.00 to $530.00 in a research report on Monday, January 27th. Stifel Nicolaus increased their price objective on shares of Intuitive Surgical from $525.00 to $610.00 and gave the company a "buy" rating in a research report on Thursday, December 5th. Finally, Leerink Partners increased their target price on Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $613.10.

Intuitive Surgical Stock Down 2.4 %

The company has a 50 day moving average of $565.45 and a 200-day moving average of $525.06. The stock has a market capitalization of $210.78 billion, a P/E ratio of 92.32, a PEG ratio of 5.85 and a beta of 1.39.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Myriam Curet sold 408 shares of the firm's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total transaction of $240,618.00. Following the transaction, the executive vice president now directly owns 353 shares of the company's stock, valued at approximately $208,181.75. This trade represents a 53.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jamie Samath sold 269 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $590.00, for a total value of $158,710.00. Following the transaction, the chief financial officer now directly owns 3,282 shares in the company, valued at $1,936,380. This trade represents a 7.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,348 shares of company stock worth $3,587,582. 0.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ISRG. Atala Financial Inc acquired a new position in Intuitive Surgical during the fourth quarter worth about $25,000. Berbice Capital Management LLC acquired a new position in Intuitive Surgical during the fourth quarter worth about $26,000. Parvin Asset Management LLC acquired a new position in Intuitive Surgical during the fourth quarter worth about $26,000. BankPlus Trust Department acquired a new position in Intuitive Surgical during the fourth quarter worth about $28,000. Finally, Hurley Capital LLC acquired a new position in Intuitive Surgical during the fourth quarter worth about $28,000. 83.64% of the stock is owned by institutional investors and hedge funds.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.